Email me your job opening if you are an employer and I’ll post it for free. If you are a job seeker, email me your info and I’ll post that for free. Job Openings 2013 for stem cells. Are you a grad student wrapping up your PhD in the next year or so? Have […]
Why invest in stem cells? Ideas are the foundation of stem cell research, but funding makes those ideas a reality. We talk a lot about governmental funding of stem cell research through CIRM and NIH. The funding from these agencies is essential and will undoubtedly lead to new treatments and cures, possibly for millions of
Why invest in stem cells? Progress, Patients, and Patents Read More »
Who’s who in the field of iPS cells? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
Stem Cell Tools CIRM CIRM TV CSHL Expert Chats on Stem Cells (very cool) Stem cell wiki European Stem Cell Portal Stem cells NIH Stem Cell NY Times article collection ISSCR Cell Stem Cell — the journal Stem Cells — the journal Stem cell video Stem Cell Chromatin info Recommended Stem Cell Blogs
How are things looking for the stem cell field for Spring 2011? Issue One. Getting to the clinic. At this point, Geron and ACT have their FDA-approved clinical trials underway using derivatives of human embryonic stem cells. As expected no news has leaked out on how things are going and it may well be Fall
Update on the stem cell field: Spring 2011 Read More »
How is Geron doing along with other stem cell biotechs? What’s going on these days with biotech companies working on stem cell-based products? Geron and ACT Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they
Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »
It’s been more than 4 years since Shinya Yamanaka published the remarkable finding that his lab could transform or “reprogram” regular cells called fibroblasts into a very unique state that was quite similar to that of embryonic stem cells (ESC). Yamanaka called these new cells “iPS cells” for induced pluripotent stem cells. iPS cells Since
The Inside Scoop on iPS cells early in 2011 Read More »
What are recent trends in Stem Cell Research Funding? My post yesterday on the problems with the current system of stem cell funding generated a lot of interest from readers– more than a dozen left comments. Many of the comments were insightful even if readers disagreed on certain points. David Jensen also posted on an
Trends in Stem Cell Research Funding: where do we go from here? Read More »
In this post I give my most interesting predictions about events in the stem cell field in 2011. Update: I’ve continuing doing predictions every year all the way through 2020 and intend to continue. See my 2012-2020 predictions here. Appeals court rules in favor of federally funded hESC research. This is more of a hope
Predictions for Stem Cells in 2011 Read More »
It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to
Challenges translating stem cell treatments to patients Read More »